NEUP vs ACAD vs INVA vs AXSM vs JPM

For growth investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger pick with 65. 5% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Innoviva, Inc. (INVA) offers the better valuation at 6. 8x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 8x versus JPMorgan Chase & Co. at 16. 2x. On forward P/E, Innoviva, Inc. is actually cheaper at 6. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 0. 61x versus JPMorgan Chase & Co. 's 0. 83x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +271. 9%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: AXSM returned +39. 6% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 03β versus Neuphoria Therapeutics Inc. 's 1. 38β — meaning NEUP is approximately 4454% more volatile than INVA relative to the S&P 500. On balance sheet safety, Neuphoria Therapeutics Inc. (NEUP) carries a lower debt/equity ratio of 1% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Axsome Therapeutics, Inc.

(AXSM) is pulling ahead at 65. 5% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -28. 7% for Axsome Therapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -26. 5% for AXSM. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 0. 61x versus JPMorgan Chase & Co. 's 0. 83x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 6. 3x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 49. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 64. 5% to $37. 00.

In this comparison, JPM (1.

8% yield) pays a dividend. NEUP, ACAD, INVA, AXSM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, NEUP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEUP (Healthcare) and ACAD (Healthcare) and INVA (Healthcare) and AXSM (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEUP is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; INVA is a small-cap high-growth stock; AXSM is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NEUP, ACAD, INVA, AXSM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.